Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Studies have shown that androgen receptor (AR) signaling activation may be one of the mechanisms, and targeting AR showed some promising results in AR-positive triple-negative breast cancer. 31434793 2020
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE In this study, we evaluated the characteristics, clinical behaviour and role of biomarkers (androgen receptor (AR), oestrogen receptor beta (ERβ) and p53) in metastatic TNBC. 31563883 2020
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. 30783520 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients' prognosis. 31319547 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE A poor DFS was observed for AR+/FOXA1+ tumors compared to other TNBCs (<i>p</i> = 0.0117). 31540486 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. 31106385 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE We examined in vivo effects of JQ1 in a xenograft model of AR expressing TNBC. 31527644 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The frequency of grade 3 tumors was lower among AR-positive TNBC tumors compared to AR-negative tumors (40 vs 86.4%, p<0.001). 30570854 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We analyzed the diagnostic value of estrogen receptor, progesterone receptor, human epidermal growth factor receptor, thyroid transcription factor-1 (TTF1), Napsin A, mammaglobin, gross cystic disease fluid protein 15 (GCDFP15), Sry-related HMg-Box gene 10 (SOX10), GATA-binding protein 3 (GATA3), and androgen receptor in a series of 207 TNBC and 152 primary lung adenocarcinomas (LA). 30628926 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Bivariate fit analysis demonstrated that QNBC (n = 224) significantly (P < .03) correlated with younger aged patients at initial biopsy compared to AR positive TNBC patients (n = 51). 30594038 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer. 30805773 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We identified Chk1 as a putative drug target in AR-positive TNBCs. 30352905 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The purpose of this study was to determine if the imaging features of TNBCs differ by AR (androgen receptor) status, which is a surrogate immunohistochemical (IHC) marker for the chemoresistant LAR subtype of TNBC. 31005169 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Recognition of these tumour subsets has opened potential avenues for therapies exploiting the AR pathway in triple negative breast carcinoma (TNBC). 30425121 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The androgen receptor (AR) is proposed as a therapeutic target for AR-positive advanced triple-negative breast cancer. 29713287 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Targeting androgen receptor (AR) in TNBC is thought to be a promising approach. 29964098 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. 30279965 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Early data from clinical trials evaluating AR antagonists in invasive/metastatic triple-negative breast cancer suggest that some patients may benefit from androgen blockade. 29489512 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Studies have shown it to antagonize estrogen receptor alpha (ERα) DNA binding, thereby preventing pro-proliferative gene transcription; whilst others have demonstrated AR to take on the mantle of a pseudo ERα particularly in the setting of triple negative breast cancer. 30416486 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Recent efforts aimed at molecular characterisation of TNBCs have revealed various emerging therapeutic targets including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, androgen receptor and epigenetic proteins. 29202431 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. 29940524 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. 29880907 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC. 29373071 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Moreover, AR stimulates cellular proliferation in triple negative breast cancer (ERα -, PgR -, and HER-2-Neu -). 30210453 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 GeneticVariation disease BEFREE p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. 29484502 2018